

PHENYL-SUBSTITUTED INDOLES AND INDAZOLES**Cross-Reference to Related Applications**

This application claims priority from U.S. Provisional Application Serial Number 60/194,071, filed on March 31, 2000, our Docket Number ORT-1158 and U.S. Provisional Application Serial Number 60/194,071, filed on February 28, 2001, our Docket Number ORT-1366.

Field of the Invention

The invention relates to pharmaceutically-active fused heterobicyclic compounds and methods of using them to treat or prevent disorders and conditions, such as those mediated by the histamine H₃ receptor.

Background

The histamine H₃ receptor is located as a presynaptic autoreceptor in the central nervous system and as a presynaptic heteroreceptor on serotonergic, noradrenergic, dopaminergic, and cholinergic neurons. The histamine H₃ receptor is also located peripherally in tissues such as vascular smooth muscle cells.

Proposed uses of histamine H₃ antagonists include the treatment or prevention of dementia, Alzheimer's disease (Panula et al. *Abstr. Society Neuroscience*, 1995, 21:1977), epilepsy (Yokoyama et al. *Eur. J. Pharmacol.*, 1993, 234:129), sleep/wake disorders (Lin et al., *Br. Res.*, 1990, 523, 325; Monti et al., *Eur. J. Pharmacol.*, 1991, 205, 283) including narcolepsy, insomnia, and jet lag, eating disorders (Machidori et al. *Brain Research*, 1992, 590:180), motion sickness, vertigo, attention deficit hyperactivity disorder, learning and memory disorders (Barnes et al. *Abstr. Society Neuroscience*, 1993, 19:1813), schizophrenia (Schlicker et al. *Naunyn Schmiedeberg's Arch. Pharmacol.*, 1996, 353:325), and sequelae associated with post-ischemic reperfusion and hypertension. (Imamura et al., *J. Pharmacol. Expt. Ther.*, 1994, 271, 1259). H₃ antagonists are also useful to treat or prevent neurogenic


inflammation such as migraine (McLeod *et al.*, *Abstr. Society Neuroscience*, 1996, 22, 2010), asthma (Ichinose *et al.*, *Eur. J. Pharmacol.*, 989, 174, 49), obesity, allergic rhinitis, substance abuse, bipolar disorders, manic disorders, and depression. Histamine H₃ antagonists alone or in combination with a histamine H₁ antagonist are believed to be useful in the treatment of upper airway allergic response or allergic rhinitis (US Patent Nos. 5217986, 5352707, and 5869479).

As noted, the prior art related to histamine H₃ ligands was comprehensively reviewed recently (*"The Histamine H₃ Receptor-A Target for New Drugs"*, Leurs, R., and Timmerman, H., (Editors), Elsevier, 1998). Within this reference the medicinal chemistry of histamine H₃ agonists and antagonists was reviewed (see Krause *et al.* and Phillips *et al.*, respectively). Thus the importance of an imidazole moiety containing only a single substitution in the 4 position was noted together with the deleterious effects of additional substitution on activity. Particularly methylation of the imidazole ring at any of the remaining unsubstituted positions was reported to strongly decrease activity.

More recently several publications have described histamine H₃ ligands that do not contain an imidazole moiety. Examples include Ganellin *et al Arch. Pharm. (Weinheim, Ger.)* 1998, 331, 395; Walczynski *et al Arch. Pharm. (Weinheim, Ger.)* 1999, 332, 389; Walczynski *et al Farmaco* 1999, 684; Linney *et al J. Med. Chem.* 2000, 2362; U.S. Patent 5,352,707; PCT Application WO99/42458, published August 26, 1999; and European Patent Application 0978512, published on February 9, 2000.

Summary of the Invention

The invention features phenyl-substituted indole and indazole compounds, methods of making them, and methods of using them. One aspect of the invention provides compounds of the following formula (I)(B):



5

wherein X_1 is CR_1 , wherein R_1 is H, halo, cyano, amino, or nitro;
and X_2 is NR_3 ;

R_3 is H, $-SO_2$ (C_{1-6} alkyl), $-SO_2$ phenyl, $(C=O)(C_{1-6}$ alkyl), or $-W'Z'$;

W' is a covalent bond, $(C=O)$, SO_2 , or C_{1-6} alkyl;

10

Z' is C_{1-6} alkyl, C_{1-6} alkoxy, C_{3-8} cycloalkyl, phenyl, or C_{2-6}
heterocyclic radical, optionally including in the ring up to 3 additional
heteroatoms or moieties independently selected from O, N, NH, S, SO,
and SO_2 ; or Z' is $NR_{13}R_{14}$ where each of R_{13} and R_{14} is independently
selected from C_{1-6} alkyl, C_{2-6} alkenyl, phenyl, benzyl, C_{3-8} cycloalkyl,
and C_{2-5} heterocyclic radical;

15

each of R_5 , R_6 , R_7 and R_8 is independently H, C_{1-6} alkyl, C_{1-6}
alkoxy, halo, nitro, or amino;

one of R_a , R_b , R_c , R_d , and R_e is WZ and the others are
independently selected from H, C_{1-6} alkyl, C_{1-6} alkoxy, halo, nitro, and
amino;

20

W is $-O-$, R_9 , $O-R_9$, NR_{10} , $-(CO)(O)R_9$, $-O(CO)R_9$,
 $-(CO)NR_{10}$, or $-N(R_{10})-CO-R_9$, wherein R_9 is C_{1-6} alkylene, C_{2-6}
alkynylene, C_{2-6} alkenylene, phenylene, or C_{2-5} heterocyclic bivalent
radical, and R_{10} is H, C_{1-6} alkyl, C_{2-6} alkynyl, C_{2-6} alkenyl, phenyl, or C_{2-5}
heterocyclic radical;

25

Z is C_{2-8} heterocyclic radical with at least one basic nitrogen atom
in the ring, optionally including in the ring up to 3 additional heteroatoms
or moieties independently selected from O, $C=O$, N, NH, NG, S, SO,
and SO_2 , wherein G is R_{15} , COR_{15} , $COOR_{15}$, SO_2R_{15} , SO_2N , CSR_{15} ; or Z
is $NR_{11}R_{12}$ where each of R_{11} and R_{12} is independently selected from H,
 C_{1-6} alkyl, phenyl, benzyl, C_{3-8} cycloalkyl, and C_{2-5} heterocyclic radical;
or $NR_{11}R_{12}$ taken together is a C_{6-8} cycloalkylimino radical; and R_{15} is C_{1-6}
alkyl, C_{2-6} alkynyl, C_{2-6} alkenyl, C_{3-7} cycloalkyl, and C_{4-7} cycloalkenyl;

30

each of the above hydrocarbyl or heterocyclic groups being optionally substituted with between 1 and 3 substituents selected from C₁₋₃ alkyl, C₁₋₃ alkoxy, halo, hydroxy, phenyl, and phenyl(C₁₋₃ alkyl); and wherein each of the above heterocyclic groups may be attached to the rest of the molecule by a carbon atom or a heteroatom;

5 or a pharmaceutically acceptable salt, amide, ester, or hydrate thereof.

According to another aspect of the invention, the disclosed compounds and certain other compounds, are useful for the treatment and/or

10 prevention of diseases and conditions mediated by the histamine 3 (H₃) receptor.

A third aspect of the invention features methods of making the disclosed compounds.

Additional features of the invention are disclosed in the following

15 description and examples, and in the appended claims.

Detailed Description

The invention features pharmaceutically active phenyl-substituted
5 indoles and indazoles and methods of making and using them. The
description is organized as follows:

- A. Terms
- B. Compounds
- C. Synthetic Methods
- 10 D. Uses (including dosages, formulations, and related compounds)
- E. Synthetic Examples
- F. Biological Examples
- G. Other Embodiments
- 15 H. Claims

A. Terms

The following terms are defined below and by their usage throughout
this disclosure.

20 "Alkyl" includes straight chain and branched hydrocarbons with at least
one hydrogen removed to form a radical group. Alkyl groups include methyl,
ethyl, propyl, isopropyl, butyl, isobutyl, t-butyl, 1-methylpropyl, pentyl,
isopentyl, sec-pentyl, hexyl, heptyl, octyl, and so on. Alkyl does not include
cycloalkyl.

25 "Alkenyl" includes straight chain and branched hydrocarbon radicals as
above with at least one carbon-carbon double bond (sp^2). Alkenyls include
ethenyl (or vinyl), prop-1-enyl, prop-2-enyl (or allyl), isopropenyl (or 1-
methylvinyl), but-1-enyl, but-2-enyl, butadienyls, pentenyls, hexa-2,4-dienyl,
and so on. Hydrocarbon radicals having a mixture of double bonds and
triple bonds, such as 2-penten-4-ynyl, are grouped as alkynyls herein.
30 Alkenyl does not include cycloalkenyl.

"Alkynyl" include straight chain and branched hydrocarbon radicals as
above with at least one carbon-carbon triple bond (sp). Alkynyls include
ethynyl, propynyls, butynyls, and pentynyls. Hydrocarbon radicals having a

mixture of double bonds and triple bonds, such as 2-penten-4-ynyl, are grouped as alkynyls herein. Alkynyl does not include cycloalkynyl.

"Alkoxy" includes a straight chain or branched alkyl group with a terminal oxygen linking the alkyl group to the rest of the molecule. Alkoxy includes methoxy, ethoxy, propoxy, isopropoxy, butoxy, t-butoxy, pentoxy and so on. "Aminoalkyl", "thioalkyl", and "sulfonylalkyl" are analogous to alkoxy, replacing the terminal oxygen atom of alkoxy with, respectively, NH (or NR), S, and SO₂.

"Aryl" includes phenyl, naphthyl, biphenyl, and so on.

"Cycloalkyl" includes cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cycloheptyl, cyclooctyl, and so on.

"Cycloalkenyl" includes cyclobutenyl, cyclobutadienyl, cyclopentenyl, cyclopentadienyl, cyclohexenyl, cyclohexadienyl, cyclohexatrienyl (phenyl), cycloheptenyl, and so on. "Cycloalkynyl" includes the analogous rings with one or more triple bonds.

"Heterocyclic radicals" include aromatic and nonaromatic rings having carbon atoms and at least one heteroatom (O, S, N) or heteroatom moiety (SO₂, CO, CONH, COO) in the ring. Unless otherwise indicated, a heterocyclic radical may have a valence connecting it to the rest of the molecule through a carbon atom, such as 3-furyl or 2-imidazolyl, or through a heteroatom, such as N-piperidyl or 1-pyrazolyl. Examples of heterocyclic radicals include thiazoyl, furyl, pyran, isobenzofuranyl, pyrrolyl, imidazolyl, pyrazolyl, isothiazolyl, isoxazolyl, pyridyl, pyrazinyl, pyrimidinyl, pyridazinyl, indolizynyl, isoindolyl, indolyl, indazolyl, purinyl, quinolyl, furazanyl, pyrrolidinyl, pyrrolinyl, imidazolidinyl, imidazolynyl, pyrazolidinyl, pyrazolinyl, piperidyl, piperazinyl, indolinyl, and morpholinyl. For example, preferred heterocyclic radicals for Z include morpholinyl, piperazinyl, pyrazinyl, pyrrolidinyl, pyridyl, cyclohexylimino, cycloheptylimino, and more preferably, piperidyl.

"halo" includes fluoro, chloro, bromo, and iodo, and preferably fluoro or chloro.

"patient" or "subject" includes mammals such as humans and animals (dogs, cats, horses, rats, rabbits, mice, non-human primates) in need of

observation, experiment, treatment or prevention in connection with the relevant disease or condition. Preferably, the patient is a human.

"composition" includes a product comprising the specified ingredients in the specified amounts as well as any product which results directly or indirectly from combinations of the specified ingredients in the specified amounts.

Concerning the various radicals in this disclosure and in the claims, two general remarks are made. The first remark concerns valency. As with all hydrocarbon radicals, whether saturated, unsaturated or aromatic, and whether or not cyclic, straight chain, or branched, and also similarly with all heterocyclic radicals, each radical includes substituted radicals of that type and monovalent, bivalent, and multivalent radicals as indicated by the context of the claims. The context will indicate that the substituent is an alkylene or hydrocarbon radical with at least two hydrogen atoms removed (bivalent) or more hydrogen atoms removed (multivalent). An example of a bivalent radical linking two parts of the molecule is W in formula (I)(B) which links Z with the phenyl group (-Ph-WZ). Subject to the claims, W can be an alkyl (strictly, alkylene) group (-Ph-CH₂CH₂CH₂-Z), an aminoalkyl group (-Ph-NH-CH₂CH₂CH₂-Z), an alkoxy group (-Ph-O-CH₂CH₂CH₂-Z), an "oxa" (-Ph-O-Z), and so on.

Second, radicals or structure fragments as defined herein are understood to include substituted radicals or structure fragments. Using "alkyl" as an example, "alkyl" should be understood to include substituted alkyl having one or more substitutions, such as between 1 and 5, 1 and 3, or 2 and 4 substituents. The substituents may be the same (dihydroxy, dimethyl), similar (chlorofluoro), or different (chlorobenzyl- or aminomethyl-substituted). Examples of substituted alkyl include haloalkyl (such as fluoromethyl, chloromethyl, difluoromethyl, perchloromethyl, 2-bromoethyl, and 3-iodocyclopentyl), hydroxyalkyl, aminoalkyl, nitroalkyl, alkylalkyl, and so on.

Preferred substitutions for phenyl include methyl, methoxy, fluoromethyl, difluoromethyl, perfluoromethyl (trifluoromethyl), 1-fluoroethyl, 2-fluoroethyl,

ethoxy, fluoro, chloro, and bromo, and particularly methyl, fluoromethyl, perfluoro, methoxy, and fluoro.

5 Examples of other substituted radicals or fragments include 1-methyl-2-pyrrolidino, 4-(piperidyl)-piperidyl, [4-(N-benzyl)piperidyl]amino, 4-fluorobenzylamino, beta-hydroxyethoxy, beta-hydroxypropoxy, 2-oxo-pyrrolidino, 4-(1-methyl-4-piperidinyl), 4-(5-methyl-thiazoyl), 4-chlorobenzyl, 4-fluorobenzyl, 4-methylbenzyl, 4-methylpiperazinyl, piperazinyl, and 4-(1-isopropyl-4-piperidinyl).

B. Compounds

One aspect of the invention features compounds of formula (I)B as described in the Summary section above. The invention encompasses the described compounds and pharmaceutically acceptable salts, esters, amides, and hydrates thereof.

Preferred compounds include those compounds of formula (I)B wherein: (a) R_3 is H or C_{1-3} alkyl; (b) R_3 is $-(C=O)C_{1-6}$ alkyl; (c) R_3 is $-SO_2(C_{1-3}$ alkyl); (d) R_3 is methylsulfonyl; (e) W' is a covalent bond; (f) W' is SO_2 or $(C=O)$; (g) R_c is WZ; (h) R_b or R_d is WZ; (i) W is ethoxy, propoxy, or butoxy; (j) W is $-O-$; (k) one of R_b , R_c , and R_e is WZ and the others are independently selected from H, methyl, ethyl, methoxy, ethoxy, amino, nitro, and halo; and R_a and R_d are each independently H or methyl; (l) at least two of the following apply: R_c is WZ; W is propoxy or ethoxy; and Z is N-piperidino, 2-(N-methyl)pyrrolidino, or N,N-dimethyl; or combinations thereof.

Additional preferred compounds include those wherein (m) Z is piperazino or N-methylpiperazino, and more preferably Z is pyrrolidino, N-methyl-pyrrolidino, pyridyl, thiazoyl, piperidino, or $NR_{11}R_{12}$ where each of R_{11} and R_{12} is independently selected from H, C_{1-6} alkyl, phenyl, benzyl, C_{3-6} cycloalkyl, and C_{2-5} heterocyclic radical or taken together with the N form a C_{6-8} cycloalkylamino radical; or wherein (m) is combined with (a) through (l) above.

Further preferred compounds include those wherein (n) one of R_b , R_c , and R_e is WZ and the others are independently selected from H, methyl, ethyl, methoxy, ethoxy, amino, and halo; and R_a and R_d are each independently H or methyl; W is $-O-$ or C_{1-3} alkoxy; Z is piperazino or N-methylpiperazino, and more preferably pyrrolidino, N-methylpyrrolidino, pyridyl, thiazoyl, piperidino, or $NR_{11}R_{12}$ where each of R_{11} and R_{12} is independently selected from H, C_{1-2} alkyl, phenyl, benzyl, C_{3-8} cycloalkyl, and C_{2-5} heterocyclic radical; each of R_6 and R_7 are each independently H, methyl, methoxy, or ethoxy; and each of R_5 and R_8 is H. Preferred compounds also include those wherein for example one or more of (a) through (n) is combined with (o) R_3 is H or $-SO_2(C_{1-6}$ alkyl); or (p) R_3 is SO_2 (phenyl) and $(C=O)(C_{1-6}$ alkyl).

Examples of more preferred compounds include: (i) 2-[4-[2-[1-(methyl)-2-pyrrolidinyl]ethoxy]phenyl]-1H-indole; 2-[4-[2-[1-(methyl)-2-pyrrolidinyl]ethoxy]phenyl]-1-(methylsulfonyl)-1H-indole; 2-[4-[3-Piperidinopropoxy]phenyl]-1H-indole; 2-[4-[3-Piperidinopropoxy]phenyl]-1-(methylsulfonyl)-1H-indole; and 2-[3-[3-Piperidinopropoxy]phenyl]-1-(methylsulfonyl)-1H-indole; and (ii) 2-(4-(3-(4-methylpiperazino)propoxy)-phenyl)indole; and 1-(methylsulfonyl)-2-(4-(3-(4-methylpiperazino)-propoxy)phenyl)indole.

Other examples of compounds, and methods of making them, are provided in the next section.

C. Synthetic Chemical Methods


The invention provides methods of making the disclosed compounds according to traditional organic synthetic methods as well as matrix or combinatorial synthetic methods. Schemes 1 through 9 describe suggested synthetic routes.

Using these Schemes, the guidelines below, and the examples in section E, a person of skill in the art may develop analogous or similar methods for a given compound.

One skilled in the art will recognize that synthesis of the compounds of the present invention may be effected by purchasing an intermediate or protected intermediate compounds described in any of the schemes disclosed herein. One skilled in the art will further recognize that during any of the processes for preparation of the compounds in the present invention, it may be necessary and/or desirable to protect sensitive or reactive groups on any of the molecules concerned. This may be achieved by means of conventional protecting groups, such as those described in "Protective Groups in Organic Synthesis", John Wiley & Sons, 1991. These protecting groups may be removed at a convenient stage using methods known from the art.

Examples of the described synthetic routes includes Synthetic Examples 1 through 17. Compounds analogous to the target compounds of these examples can be, and in many cases, have been, made according to similar routes. The disclosed compounds are useful in basic research and as pharmaceutical agents as described in the next section.


Scheme I



- 5 Generally, a compound of formula (V), a known compound or compound prepared by known methods, is reacted with a compound of formula (II), a known compound or compound prepared by known methods, in the presence of a palladium catalyst such as dichlorobis(triphenylphosphine) palladium, and

CuI, or the like, in the presence of a base such as triethylamine, or the like, in a solvent such as DMF, THF, DMA, and the like, to yield the corresponding compound of formula (IV). Compound (IV) is then further reacted, as outlined in Schemes 5-7 below, to form the compound of formula (I). Alternatively a compound of formula (III) can be reacted with a compound of formula (II) using the above described, or similar methods to form a compound of formula (I) directly. In addition compounds of formula (I), in which X_2 is NH can be obtained by reacting a compound of formula (VI) with an aromatic hydrazine of formula (VII) in the presence of a strong acid such as PPA.

Compounds of formula (II) wherein R_3 is chosen from either $-\text{SO}_2(\text{C}_{1-6} \text{ alkyl})$, $-\text{SO}_2$ phenyl, $(\text{C}=\text{O})(\text{C}_{1-6} \text{ alkyl})$, and R_5-R_8 are selected from H, $\text{C}_{1-6} \text{ alkyl}$, $\text{C}_{1-6} \text{ alkoxy}$, halo, nitro, may be prepared according to the process outlined in Scheme 2.




A compound of formula (VIII), wherein R_5-R_8 are selected from H, $\text{C}_{1-6} \text{ alkyl}$, $\text{C}_{1-6} \text{ alkoxy}$, halo, nitro, a known compound or compound prepared by known methods, is treated with an iodinating agent such as N-iodo succinamide, ICl, or I_2 in a solvent such as acetic acid, acetonitrile, or the like, to yield the corresponding compound of formula (IX). The compound (IX), a known compound or compound prepared by known methods, is reacted with a compound of formula (XI), in which R_3 is chosen from either $-\text{SO}_2(\text{C}_{1-6} \text{ alkyl})$, $-\text{SO}_2\text{phenyl}$, $(\text{C}=\text{O})(\text{C}_{1-6} \text{ alkyl})$, $(\text{C}=\text{O})(\text{C}_{1-6} \text{ alkoxy})$, $(\text{C}=\text{O})\text{phenyl}$, and X_3 is selected from Br, Cl, F, or a conventional activating anhydride, or ester, in the presence of a base such as pyridine, N,N-dimethyl aminopyridine, triethylamine, or sodium hydroxide in an organic solvent such as DCM, THF, or DMF to yield the corresponding compound of formula (II).

Compounds of formula (V) wherein W is OH, NH₂, CO₂H, and Ra-Re are selected from H, C₁₋₆ alkyl, C₁₋₆ alkoxy, halo, or nitro may be prepared according to the processes outlined in Scheme 3.

5


Scheme 3



A compound of formula (X) wherein W is OH, NH₂, CO₂H, and Ra-Re are selected from H, C₁₋₆ alkyl, C₁₋₆ alkoxy, halo, or nitro, is reacted with a
 10 diazophosphonate in the presence of a base such as, K₂CO₃, KOH, or DBU, in a solvent such as MeOH, EtOH, or DMF, to yield compounds of formula (V). Alternately compounds of formula (V) can also be prepared by treating a compound of formula (X) with trimethylsilyldiazomethane, in the presence of a strong base such as LDA or LHMDS, in a solvent such as, THF, Ether, or
 15 MTBE, to yield compounds of formula (V). In addition compounds of formula (V) may also be obtained using methods known to one skilled in the art as outlined in R. C. Larock "Comprehensive Organic Transformations", VCH Publishers, 1989, p. 295-296.

Specifically compounds of formula (IV) wherein W is -OH, -NH₂, -
 20 C(O)OH may be prepared according to the processes outlined in Scheme 4.

Scheme 4




25 Specifically, Compounds of formula (II), as defined in Scheme 2, are combined with compounds of formula (V), as defined in Scheme 3, in the

presence of a palladium catalyst such as, $\text{Pd}(\text{PPh}_3)_2\text{Cl}_2$, or $\text{Pd}(\text{OAc})_2$, and a copper source such as CuI , CuOAc , or CuBr , and a base such as triethylamine or pyridine, in a solvent such as THF or DMF, to provide the corresponding compounds of formula (IV).

- 5 Compounds of formula (I) in which n is a whole number between 0 and 4, and Z is as described in claim (1), and $\text{R}_5\text{-R}_8$ and $\text{R}_a\text{-R}_e$ are as described in Scheme 4, can be obtained by the procedures described in Scheme 5-7.

Scheme 5

10




- Specifically a compound of formula (IVa) wherein R_3 , $\text{R}_a\text{-R}_e$ and $\text{R}_5\text{-R}_8$ are as described in Scheme 4, is reacted with an alcohol of formula (XII), wherein Z is as described in claim (1), and n is a whole number between 0 and 4, in the presence of a phosphine such as triphenyl phosphine, polymer supported triphenylphosphine, or tributylphosphine, and an azodicarboxylate such as diisopropylazodicarboxylate, 1,1'-(azodicarbonyl)dipiperidine, or other Mitsunobu conditions, in a solvent such as DCM or THF, to afford the corresponding compounds of formula (I) in which X_4 is a covalent bond, and n is a whole number between 0 and 4.

- Alternatively compounds of formula (IV) as described above, can be reacted with carboxylic acids of formula (XIII), in which Z is defined as above, and n is a whole number between 0 and 3, in the presence of an activating agent such as carbonyldiimidazole or thionyl chloride, with a base such as N -methyl morpholine, triethylamine, or N,N -dimethyl-4-aminopyridine to yield the corresponding compound of formula (I), in which X_4 is defined as a carbonyl group.

Alternatively compounds of formula (Ib) can be obtained by the methods described in Scheme 6.


Scheme 6



Specifically, a compound of formula (IVb) in which R₃, R₅-R₈ and R_a-R_e is as defined in scheme 4, is reacted with an aldehyde of formula (XIV) in which n is a whole number between 0 and 3, and Z is as described in claim (1), in the presence of a reducing agent such as NaBH₃(CN) or NaBH(OAc)₃, in a solvent such as MeOH or THF, to afford the corresponding compound of formula (I).

Alternatively, compounds of formula (Ic) can be obtained using the methods outlined in Scheme 7.


Scheme 7



Specifically, a compound of formula (IVc) in which R₃, R₅-R₈, and R_a-R_e is defined as in Scheme 4, is reacted with an alcohol of formula (XII), or an amine of formula (XV), in which Z is as defined in Claim (1), and n is a whole number between 0 and 4, in the presence of an activating agent such as carbonyldiimidazole or thionyl chloride, with a base such as N-methylmorpholine, triethylamine, or N,N-dimethyl-4-aminopyridine to yield the corresponding compound of formula (I), in which X₅ is defined as O or NH.

In addition, compounds of formula (I)B can be converted to other compounds of formula (I)B as defined in Scheme 8 below.

Scheme 8



Specifically, a compound of formula (Id) in which R_3 , R_5-R_8 , and R_a-R_e are as described in Scheme 4, is treated with; a nitrating agent such as HNO_3 or an electrophilic halogenating agent such as Br_2 or NIS , using solvents and conditions known to one skilled in the art, to yield the corresponding compound of formula (If) in which R_1 is defined as NO_2 , Br , Cl , or I . Additionally a compound of formula (If) in which R_1 is NO_2 can be further elaborated through reduction with an appropriate reducing agent such as SnCl_2 or iron metal, to yield the corresponding compound of formula (Ie), in which R_1 is NH_2 .


Additionally, compounds of formula (Ie) in which R_3 is defined as in Scheme 2, and R_5-R_8 , and R_a-R_e are as described in Scheme 4, can be treated with a strong base such as KOH , K_2CO_3 , or the like, in a solvent such as THF, MeOH, or the like, to yield the corresponding compounds of formula (If).

In addition, compounds of formula (If) can be converted to compounds of the corresponding formula (Ie) by treatment with a strong base such as $n\text{-BuLi}$, NaH , or the like, and an alkylating or acylating agent of formula (XI), wherein R_3 and X_3 are as defined in Scheme 2.

The synthesis of compounds of formula (III) in which R_a-R_e are as defined in Scheme 3, R_{11} , and R_{12} are as defined claim (1), and n is an integer

[illegible]

Scheme 9




5 Specifically, a compound of formula (XVI) in which R₁₃ is H, or C₁₋₆ alkyl, and R_a-R_e is as previously described, is treated with a base such as NaH or K₂CO₃, and a compound of formula (XVIII), in which X₆ is selected from Cl, Br, I, -OSO₂CH₃, -OTs, or OTf, and X₇ is selected from the same definition as X₆ but less reactive than the element chosen for X₆, and n is an integer from 2 to 10 5, in a solvent such as THF, DMF or DMSO, to yield the corresponding compound of formula (XVII). The compound of formula (XVII) is then treated with a compound of formula (XIX), wherein R₁₁ and R₁₂ are as defined in Claim (1), in a solvent such as DMF or DCM, to afford the corresponding compound of formula (VI).

15 Compounds of formula (III) are prepared by treatment of corresponding compounds of formula (IV), in which R₁₃ is defined as H, with a base such as LDA or LIHMDS, and TMSCHN₂, in a solvent such as THF, diethylether, or the like. Alternately, compounds of formula (III) can also be prepared by treating corresponding compounds of formula (IV), with a base such as K₂CO₃ or KOH, 20 and a phosphonate such as (CH₃O)₂P(O)C(N₂)C(O)CH₃, in a solvent such as MeOH.

Compounds of formula (Ig) can be obtained using the methods described in Scheme 10.


Scheme 10



5 Specifically a compound of formula (VI) as defined in scheme 9 is treated with an aryl hydrazine of formula (VII), wherein R₅-R₈ is as defined as in claim (1), in polyphosphoric acid, to yield the corresponding compound of formula (Ig).

10 Additionally compounds of formula (I) can be formed using the procedures outlined in Scheme 11.

Scheme 11



15 Specifically a compound of formula (II), as defined in Scheme 2 is combined with a compound of formula (III) as defined in Scheme 9, in the presence of a palladium catalyst such as Pd(PPh₃)₂Cl₂ or Pd(OAc)₂, and a copper source such as CuI, CuOAc or CuBr, and a base such as triethylamine or pyridine, in a solvent such as THF or DMF, to provide the corresponding compounds of formula (Ih).

20

D. Uses

25 According to the invention, the disclosed compounds and compositions are useful for the amelioration of symptoms associated with, the treatment of, and/or the prevention of, the following conditions and diseases, or symptoms associated with them: dementia, Alzheimer's disease, narcolepsy, eating disorders, motion sickness, vertigo, attention deficit hyperactivity disorder,

learning and memory disorders, schizophrenia, mild cognitive impairment
upper airway allergic response (allergic rhinitis), insomnia, jet lag, obesity,
asthma, neurogenic inflammation, substance abuse, bipolar disorders, manic
disorders, and depression. The invention also features pharmaceutical
5 compositions, which include, without limitation, one or more of the disclosed
compounds, and a pharmaceutically acceptable carrier or excipient.

1. Dosages

Those skilled in the art will be able to determine, according to known
methods, the appropriate dosage for a patient, taking into account factors such
10 as age, weight, general health, the type of symptoms requiring treatment, and
the use of other medications. An effective amount means that amount of
pharmaceutical reagent (such as a prodrug, metabolic precursor, or active
compound) that elicits the biological or medical response desired. In general, a
therapeutically effective amount will be between 0.01 and 1000 mg/kg per day,
15 preferably between 0.01 and 250 mg/kg body weight, and daily dosages will be
between 0.50 and 5000 mg for an adult subject of normal weight. Capsules,
tablets or other formulations (such as liquids and film-coated tablets) may be of
between 0.20 and 100 mg, such as 0.20, 0.50, 1.0, 2.0, 3.0, and 10 mg and
can be administered according to the disclosed methods.

20 2. Formulations

Dosage unit forms include tablets, capsules, pills, powders, granules,
aqueous and nonaqueous oral solutions and suspensions, and parenteral
solutions packaged in containers adapted for subdivision into individual doses.
Dosage unit forms can also be adapted for various methods of administration,
25 including controlled release formulations, such as subcutaneous implants.
Administration methods include oral, rectal, parenteral (intravenous,
intramuscular, subcutaneous), intracisternal, intravaginal, intraperitoneal,
intravesical, local (drops, powders, ointments, gels or cream), and by inhalation
(a buccal or nasal spray) as appropriate depending on the overall health and
30 condition of the patient as determined by a physician or veterinary doctor.

Parenteral formulations include pharmaceutically acceptable aqueous or
nonaqueous solutions, dispersion, suspensions, emulsions, and sterile
powders for the preparation thereof. Examples of carriers include water,

ethanol, polyols (propylene glycol, polyethylene glycol), vegetable oils, and injectable organic esters such as ethyl oleate. Fluidity can be maintained by the use of a coating such as lecithin, a surfactant, or maintaining appropriate particle size. Carriers for solid dosage forms include (a) fillers or extenders, (b) binders, (c) humectants, (d) disintegrating agents, (e) solution retarders, (f) absorption accelerators, (g) adsorbants, (h) lubricants, (i) buffering agents, and (j) propellants.

Compositions may also contain adjuvants such as preserving, wetting, emulsifying, and dispensing agents; antimicrobial agents such as parabens, chlorobutanol, phenol, and sorbic acid; isotonic agents such as a sugar or sodium chloride; absorption-prolonging agents such as aluminum monostearate and gelatin; and absorption-enhancing agents.

3. Combination Therapy

The present invention also provides compositions and methods useful for the treatment of disorders or conditions modulated, preferably antagonized, by the histamine H₃ receptor in combination with compounds that modulate other receptors including, but not limited to, histamine H₁ and histamine H₂ receptors. The present invention includes compounds and compositions useful in methods of combination therapy for the treatment of diseases or conditions modulated by the histamine H₃ receptor in combination with compounds that are selective serotonin re-uptake inhibitors (SSRIs), such as PROZAC™, or are selective norepinephrine uptake inhibitors. Such combination methods include (a) administering the two or more pharmaceutical agents separately formulated and at separate times, and (b) administering the two or more agents simultaneously in a single formulation or in separate formulations administered more or less at the same time. For example, one aspect is a method of treatment comprising administering at least one histamine H₃ receptor modulating compound disclosed herein and administering at least one compound selected from a histamine H₁ receptor modulating compound, a histamine H₂ receptor modulating compound, a selective serotonin reuptake inhibitor (such as PROZAC™), or a selective norepinephrine uptake inhibiting compound.

4. Related Compounds

The invention provides the disclosed compounds and closely related, pharmaceutically acceptable forms of the disclosed compounds, such as salts, esters, amides, acids, hydrates or solvated forms thereof; masked or protected forms; and racemic mixtures, or enantiomerically or optically pure forms.

Pharmaceutically acceptable salts, esters, and amides include carboxylate salts (e.g., C₁₋₈ alkyl, cycloalkyl, aryl, heteroaryl, or non-aromatic heterocyclic) amino acid addition salts, esters, and amides which are within a reasonable benefit/risk ratio, pharmacologically effective and suitable for contact with the tissues of patients without undue toxicity, irritation, or allergic response. Representative salts include hydrobromide, hydrochloride, sulfate, bisulfate, nitrate, acetate, oxalate, valerate, oleate, palmitate, stearate, laurate, borate, benzoate, lactate, phosphate, tosylate, citrate, maleate, fumarate, succinate, tartrate, naphthylate, mesylate, glucoheptonate, lactobionate, and laurylsulfonate. These may include alkali metal and alkali earth cations such as sodium, potassium, calcium, and magnesium, as well as non-toxic ammonium, quaternary ammonium, and amine cations such as tetramethyl ammonium, methylamine, trimethylamine, and ethylamine. See example, S.M. Berge, et al., "Pharmaceutical Salts," J. Pharm. Sci., 1977, 66:1-19 which is incorporated herein by reference. Representative pharmaceutically acceptable amides of the invention include those derived from ammonia, primary C₁₋₆ alkyl amines and secondary di (C₁₋₆ alkyl) amines. Secondary amines include 5- or 6-membered heterocyclic or heteroaromatic ring moieties containing at least one nitrogen atom and optionally between 1 and 2 additional heteroatoms. Preferred amides are derived from ammonia, C₁₋₃ alkyl primary amines, and di (C₁₋₂ alkyl)amines. Representative pharmaceutically acceptable esters of the invention include C₁₋₇ alkyl, C₅₋₇ cycloalkyl, phenyl, and phenyl(C₁₋₆)alkyl esters. Preferred esters include methyl esters.

The invention also includes disclosed compounds having one or more functional groups (e.g., hydroxyl, amino, or carboxyl) masked by a protecting group. See, e.g., Greene and Wuts, Protective Groups in Organic Synthesis, 3rd ed., (1999) John Wiley & Sons, NY. Some of these masked or protected

[illegible]

HYDROXYL PROTECTING GROUPS

Protection for the hydroxyl group includes methyl ethers, substituted
 5 methyl ethers, substituted ethyl ethers, substitute benzyl ethers, and silyl
 ethers.

Substituted Methyl Ethers

Examples of substituted methyl ethers include methoxymethyl,
 methylthiomethyl, *t*-butylthiomethyl, (phenyldimethylsilyl)methoxymethyl,
 10 benzyloxymethyl, *p*-methoxybenzyloxymethyl, (4-methoxyphenoxy)methyl,
 guaiacolmethyl, *t*-butoxymethyl, 4-pentenylloxymethyl, siloxymethyl, 2-
 methoxyethoxymethyl, 2,2,2-trichloroethoxymethyl, bis(2-chloroethoxy)methyl,
 2-(trimethylsilyl)ethoxymethyl, tetrahydropyranyl, 3-bromotetrahydropyranyl,
 tetrahydrothiopyranyl, 1-methoxycyclohexyl, 4-methoxytetrahydropyranyl, 4-
 15 methoxytetrahydrothiopyranyl, 4-methoxytetrahydrothiopyranyl S,S-dioxido, 1-
 [(2-chloro-4-methyl)phenyl]-4-methoxypiperidin-4-yl, 1,4-dioxan-2-yl,
 tetrahydrofuranyl, tetrahydrothiofuranyl and 2,3,3a,4,5,6,7,7a-octahydro-7,8,8-
 trimethyl-4,7-methanobenzofuran-2-yl.

20 Substituted Ethyl Ethers

Examples of substituted ethyl ethers include 1-ethoxyethyl, 1-(2-
 chloroethoxy)ethyl, 1-methyl-1-methoxyethyl, 1-methyl-1-benzyloxyethyl, 1-
 methyl-1-benzyloxy-2-fluoroethyl, 2,2,2-trichloroethyl, 2-trimethylsilylethyl, 2-
 (phenylselenyl)ethyl, *t*-butyl, allyl, *p*-chlorophenyl, *p*-methoxyphenyl, 2,4-
 25 dinitrophenyl, and benzyl.

Substituted Benzyl Ethers

Examples of substituted benzyl ethers include *p*-methoxybenzyl, 3,4-
 dimethoxybenzyl, *o*-nitrobenzyl, *p*-nitrobenzyl, *p*-halobenzyl, 2,6-
 30 dichlorobenzyl, *p*-cyanobenzyl, *p*-phenylbenzyl, 2- and 4-picolyl, 3-methyl-2-
 picolyl N-oxido, diphenylmethyl, *p*, *p'*-dinitrobenzhydryl, 5-dibenzosuberyl,
 triphenylmethyl, α -naphthyldiphenylmethyl, *p*-methoxyphenyldiphenylmethyl,
 di(*p*-methoxyphenyl)phenylmethyl, tri(*p*-methoxyphenyl)methyl, 4-(4'-

bromophenacyloxy)phenyldiphenylmethyl, 4,4',4''-tris(4,5-dichlorophthalimidophenyl)methyl, 4,4',4''-tris(levulinoyloxyphenyl)methyl, 4,4',4''-tris(benzoyloxyphenyl)methyl, 3-(1-midazol-1-ylmethyl)bis(4',4''-dimethoxyphenyl)methyl, 1,1-bis(4-methoxyphenyl)-1'-pyrenylmethyl, 9-anthryl, 9-(9-phenyl)xanthenyl, 9-(9-phenyl-10-oxo)anthryl, 1,3-benzodithiolan-2-yl, and benzoisothiazolyl S,S-dioxido.

Silyl Ethers

Examples of silyl ethers include trimethylsilyl, triethylsilyl, triisopropylsilyl, dimethylisopropylsilyl, diethylisopropylsilyl, dimethylhexylsilyl, *t*-butyldimethylsilyl, *t*-butyldiphenylsilyl, tribenzylsilyl, tri-*p*-xylylsilyl, triphenylsilyl, diphenylmethylsilyl, and *t*-butylmethoxyphenylsilyl.

Esters

In addition to ethers, a hydroxyl group may be protected as an ester. Examples of esters include formate, benzoylformate, acetate, chloroacetate, dichloroacetate, trichloroacetate, trifluoroacetate, methoxyacetate, triphenylmethoxyacetate, phenoxyacetate, *p*-chlorophenoxyacetate, *p*-*P*-phenylacetate, 3-phenylpropionate, 4-oxopentanoate(levulinate), 4,4-(ethylenedithio)pentanoate, pivaloate, adamantate, crotonate, 4-methoxycrotonate, benzoate, *p*-phenylbenzoate, 2,4,6-trimethylbenzoate(mesitoate)

Carbonates

Examples of carbonate protecting groups include methyl, 9-fluorenylmethyl, ethyl, 2,2,2-trichloroethyl, 2-(trimethylsilyl)ethyl, 2-(phenylsulfonyl)ethyl, 2-(triphenylphosphonio)ethyl, isobutyl, vinyl, allyl, *p*-nitrophenyl, benzyl, *p*-methoxybenzyl, 3,4-dimethoxybenzyl, *o*-nitrobenzyl, *p*-nitrobenzyl, *S*-benzyl thiocarbonate, 4-ethoxy-1-naphthyl, and methyl dithiocarbonate.

Assisted Cleavage

Examples of assisted cleavage include 2-iodobenzoate, 4-azidobutyrate, 4-nitro-4-methylpentanoate, *o*-(dibromomethyl)benzoate, 2-formylbenzenesulfonate, 2-(methylthiomethoxy)ethyl carbonate, 4-(methylthiomethoxy)butyrate, and 2-(methylthiomethoxymethyl)benzoate.

Miscellaneous Esters

Examples of miscellaneous esters include 2,6-dichloro-4-methylphenoxyacetate, 2,6-dichloro-4-(1,1,3,3-tetramethylbutyl)phenoxyacetate, 2,4-bis(1,1-dimethylpropyl)phenoxyacetate, chlorodiphenylacetate, isobutyrate, monosuccinoate, (E)-2-methyl-2-butenate(tigloate), *o*-(methoxycarbonyl)benzoate, *p*-P-benzoate, α -naphthoate, nitrate, alkyl N,N,N',N'-tetramethylphosphorodiamidate, N-phenylcarbamate, borate, dimethylphosphinothioyl, and 2,4-dinitrophenylsulfenate

Sulfonates

Examples of sulfonates include sulfate, methanesulfonate(mesylate), benzyisulfonate, and tosylate.

AMINO PROTECTING GROUPS

Protection for the amino group includes carbamates, amides, and special -NH protective groups.

Examples of carbamates include methyl and ethyl carbamates, substituted ethyl carbamates, assisted cleavage carbamates, photolytic cleavage carbamates, urea-type derivatives, and miscellaneous carbamates.

Carbamates

Examples of methyl and ethyl carbamates include methyl and ethyl, 9-fluorenylmethyl, 9-(2-sulfo)fluorenylmethyl, 9-(2,7-dibromo)fluorenylmethyl, 2,7-

di-*t*-butyl-[9-(10,10-dioxo-10,10,10-tetrahydrothioxanthyl)]methyl, and 4-methoxyphenacyl.

Substituted Ethyl

5 Examples of substituted ethyl carbamates include 2,2,2-trichloroethyl, 2-trimethylsilylethyl, 2-phenylethyl, 1-(1-adamantyl)-1-methylethyl, 1,1-dimethyl-2-haloethyl, 1,1-dimethyl-2,2-dibromoethyl, 1,1-dimethyl-2,2,2-trichloroethyl, 1-methyl-1-(4-biphenyl)ethyl, 1-(3,5-di-*t*-butylphenyl)-1-methylethyl, 2-(2'- and 4'-pyridyl)ethyl, 2-(*N,N*-dicyclohexylcarboxamido)ethyl, *t*-butyl, 1-adamantyl, 10 vinyl, allyl, 1-isopropylallyl, cinnamyl, 4-nitrocinnamyl, 8-quinolyl, *N*-hydroxypiperidinyl, alkylidithio, benzyl, *p*-methoxybenzyl, *p*-nitrobenzyl, *p*-bromobenzyl, *p*-chlorobenzyl, 2,4-dichlorobenzyl, 4-methylsulfinylbenzyl, 9-anthrylmethyl and diphenylmethyl.

Assisted Cleavage

15 Examples of assisted cleavage include 2-methylthioethyl, 2-methylsulfonylethyl, 2-(*p*-toluenesulfonyl)ethyl, [2-(1,3-dithianyl)]methyl, 4-methylthiophenyl, 2,4-dimethylthiophenyl, 2-phosphonioethyl, 2-triphenylphosphonioisopropyl, 1,1-dimethyl-2-cyanoethyl, *m*-chloro-*p*- 20 acyloxybenzyl, *p*-(dihydroxyboryl)benzyl, 5-benzisoxazolylmethyl, and 2-(trifluoromethyl)-6-chromonylmethyl.

Photolytic Cleavage

25 Examples of photolytic cleavage include *m*-nitrophenyl, 3,5-dimethoxybenzyl, *o*-nitrobenzyl, 3,4-dimethoxy-6-nitrobenzyl, and phenyl(*o*-nitrophenyl)methyl.

Urea-Type Derivatives

30 Examples of urea-type derivatives include phenothiazinyl-(10)-carbonyl derivative, *N'*-*p*-toluenesulfonylaminocarbonyl, and *N'*-phenylaminothiocarbonyl.

Miscellaneous Carbamates

Examples of miscellaneous carbamates include *t*-amyl, *S*-benzyl thiocarbamate, *p*-cyanobenzyl, cyclobutyl, cyclohexyl, cyclopentyl, cyclopropylmethyl, *p*-decyloxybenzyl, diisopropylmethyl, 2,2-dimethoxycarbonylvinyl, *o*-(*N,N*-dimethylcarboxamido)benzyl, 1,1-dimethyl-3-(*N,N*-dimethylcarboxamido)propyl, 1,1-dimethylpropynyl, di(2-pyridyl)methyl, 2-furanylmethyl, 2-iodoethyl, isobornyl, isobutyl, isonicotinyl, *p*-(*p*'-methoxyphenylazo)benzyl, 1-methylcyclobutyl, 1-methylcyclohexyl, 1-methyl-1-cyclopropylmethyl, 1-methyl-1-(3,5-dimethoxyphenyl)ethyl, 1-methyl-1-(*p*-phenylazophenyl)ethyl, 1-methyl-1-phenylethyl, 1-methyl-1-(4-pyridyl)ethyl, phenyl, *p*-(phenylazo)benzyl, 2,4,6-tri-*t*-butylphenyl, 4-(trimethylammonium)benzyl, and 2,4,6-trimethylbenzyl.

Examples of amides include:

15 Amides

N-formyl, *N*-acetyl, *N*-chloroacetyl, *N*-trichloroacetyl, *N*-trifluoroacetyl, *N*-phenylacetyl, *N*-3-phenylpropionyl, *N*-picolinoyl, *N*-3-pyridylcarboxamide, *N*-benzoylphenylalanyl derivative, *N*-benzoyl, *N-p*-phenylbenzoyl.

20 Assisted Cleavage

N-*o*-nitrophenylacetyl, *N*-*o*-nitrophenoxyacetyl, *N*-acetoacetyl, (*N*'-dithiobenzyloxycarbonylamino)acetyl, *N*-3-(*p*-hydroxyphenyl)propionyl, *N*-3-(*o*-nitrophenyl)propionyl, *N*-2-methyl-2-(*o*-nitrophenoxy)propionyl, *N*-2-methyl-2-(*o*-phenylazophenoxy)propionyl, *N*-4-chlorobutyryl, *N*-3-methyl-3-nitrobutyryl, *N*-*o*-nitrocinnamoyl, *N*-acetylmethionine derivative, *N*-*o*-nitrobenzoyl, *N*-*o*-(benzoyloxymethyl)benzoyl, and 4,5-diphenyl-3-oxazolin-2-one.

Cyclic Imide Derivatives

N-phthalimide, *N*-dithiasuccinoyl, *N*-2,3-diphenylmaleoyl, *N*-2,5-dimethylpyrrolyl, *N*-1,1,4,4-tetramethyldisilylazacyclopentane adduct, 5-substituted 1,3-dimethyl-1,3,5-triazacyclohexan-2-one, 5-substituted 1,3-dibenzyl-1,3,5-triazacyclohexan-2-one, and 1-substituted 3,5-dinitro-4-pyridonyl.

SPECIAL – NH PROTECTIVE GROUPS

5 Examples of special NH protective groups include

N-Alkyl and N-Aryl Amines

N-methyl, N-allyl, N-[2-(trimethylsilyl)ethoxy]methyl, N-3-acetoxypentyl,
N-(1-isopropyl-4-nitro-2-oxo-3-pyrrolin-3-yl), quaternary ammonium salts, N-
10 benzyl, N-di(4-methoxyphenyl)methyl, N-5-dibenzosuberonyl, N-triphenylmethyl,
N-(4-methoxyphenyl)diphenylmethyl, N-9-phenylfluorenyl, N-2,7-dichloro-9-
fluorenylmethylene, N-ferrocenylmethyl, and N-2-picolyamine N'-oxide.

Imine Derivatives

15 N-1,1-dimethylthiomethylene, N-benzylidene, N-*p*-methoxybenzylidene,
N-diphenylmethylene, N-[(2-pyridyl)mesityl]methylene, and N-(N',N'-
dimethylaminomethylene).

20 PROTECTION FOR THE CARBOXYL GROUP

Substituted Methyl Esters

Examples of substituted methyl esters include 9-fluorenylmethyl,
methoxymethyl, methylthiomethyl, tetrahydropyranyl, tetrahydrofuranyl,
25 methoxyethoxymethyl, 2-(trimethylsilyl)ethoxymethyl, benzyloxymethyl,
phenacyl, *p*-bromophenacyl, α -methylphenacyl, *p*-methoxyphenacyl,
carboxamidomethyl, and N-phthalimidomethyl.

2-Substituted Ethyl Esters

30 Examples of 2-substituted ethyl esters include 2,2,2-trichloroethyl,
2-haloethyl, ω -chloroalkyl, 2-(trimethylsilyl)ethyl, 2-methylthioethyl, 1,3-
dithianyl-2-methyl, 2-(*p*-nitrophenylsulfenyl)ethyl, 2-(*p*-toluenesulfonyl)ethyl,

2-(2'-pyridyl)ethyl, 2-(diphenylphosphino)ethyl, 1-methyl-1-phenylethyl, *t*-butyl, cyclopentyl, cyclohexyl, allyl, 3-buten-1-yl, 4-(trimethylsilyl)-2-buten-1-yl, cinnamyl, α -methylcinnamyl, phenyl, *p*-(methylmercapto)phenyl and benzyl.

5 Substituted Benzyl Esters

Examples of substituted benzyl esters include triphenylmethyl, diphenylmethyl, bis(*o*-nitrophenyl)methyl, 9-anthrylmethyl, 2-(9,10-dioxo)anthrylmethyl, 5-dibenzosuberyl, 1-pyrenylmethyl, 2-(trifluoromethyl)-6-chromylmethyl, 2,4,6-trimethylbenzyl, *p*-bromobenzyl, *o*-nitrobenzyl, *p*-nitrobenzyl, *p*-methoxybenzyl, 2,6-dimethoxybenzyl, 4-(methylsulfinyl)benzyl, 4-sulfobenzyl, piperonyl, 4-picolyl and *p*-P-benzyl.

15 Silyl Esters

Examples of silyl esters include trimethylsilyl, triethylsilyl, *t*-butyldimethylsilyl, *i*-propyldimethylsilyl, phenyldimethylsilyl and di-*t*-butylmethylsilyl.

20 Activated Esters

Examples of activated esters include thiols.

25 Miscellaneous Derivatives

Examples of miscellaneous derivatives include oxazoles, 2-alkyl-1,3-oxazolines, 4-alkyl-5-oxo-1,3-oxazolidines, 5-alkyl-4-oxo-1,3-dioxolanes, ortho esters, phenyl group and pentaaminocobalt(III) complex.

30 Stannyl Esters

Examples of stannyl esters include triethylstannyl and tri-*n*-butylstannyl.

AMIDES AND HYDRAZIDES


Amides

[illegible]

5

Examples of hydrazides include N-phenyl and N,N'-diisopropyl hydrazides.

E. Chemical Examples

Example 1

2-[4-[3-piperidinopropoxy]phenyl]-1-(methanesulfonyl)-1H-indole
 $K_i = 7 \text{ nM}$

10 Step A Preparation of 2-iodo-N-(methanesulfonyl)aniline

Methanesulfonyl chloride (4.4 mL, 57 mmol) was added to a 0° C dichloromethane (200 mL) solution containing 2-iodoaniline (5.0 g, 23 mmol) and triethylamine (9.6 mL, 69 mmol). The resulting mixture was stirred for 90 minutes, washed with HCl (0.5 M). The organics were separated then dried over sodium sulfate and concentrated in vacuo. The residue was then treated with potassium hydroxide (2.0 M in 1:1 methanol:water, 75 mL) for 30 min. This material was then diluted with dichloromethane and washed with HCl (1.0 N, 300 mL). The organics were separated then dried over sodium sulfate and concentrated to provide the title compound (5.15 g) as a tan solid.

Step B Preparation of 4-(methoxyethoxymethyl)benzaldehyde

Sodium hydride (2.4g (60%), 60 mmol) was added to 4-hydroxybenzaldehyde (6.0 g, 50 mmol) in N, N-dimethylformamide (100 mL). The suspension was stirred for 1 hour and then treated with 2-methoxyethoxymethyl chloride (6.8 mL, 60 mmol), and allowed to stir an additional 16 hours. The reaction was then partitioned between water and ether:ethyl acetate (1:1). The organics were then washed with water (4x), dried (potassium carbonate), and concentrated. The crude materials were then purified by silica gel chromatography (hexanes:ethyl acetate) to afford the title compound (9.0 g)

Step C Preparation of 1-ethynyl-4-(methoxyethoxymethyl)benzene

Dimethyl[(2-diazo-3-oxo)propyl] phosphonate was added in 4 portions to a suspension of potassium carbonate (4.96 g, 36 mmol), the product of Step B (3.78 g, 18 mmol), and methanol (50 mL). The reaction was stirred for 16 hours. and concentrated in vacuo. The residue was taken up in ether, washed with water (3x), dried (potassium carbonate), and concentrated. The crude product was purified by silica gel chromatography (hexane:ethyl acetate) to provide the title compound (2.3 g).

10 Step D Preparation of 2-(4-(methoxyethoxymethyl)phenyl)-1-(methanesulfonyl)indole

The products of Step A (3.0 g, 10 mmol) and step C (2.2 g, 10 mmol) were combined in N, N-dimethylformamide (20 mL) and triethylamine (5 mL). The solution was then treated with dichlorobis(triphenylphosphine)palladium(II) (0.7 g, 1.0 mmol), copper(I)iodide (380 mg, 2.0 mmol), and stirred at 80 °C for 17 hours. The reaction was then diluted with ether:ethyl acetate (1:1, 200 mL), washed with water (5x), dried (potassium carbonate), and concentrated in vacuo. The crude material was then purified by silica gel chromatography (hexane:ethyl acetate) to afford the title compound (3.36 g).

20

Step E Preparation of 2-(4-hydroxyphenyl)-1-(methanesulfonyl)-indole

A solution of the product of Step D (1.5 g, 4.0 mmol) in methanol (10 mL) was treated with HCl (10 mL, 4 N in dioxane). The reaction was allowed to stir for 2 hr, concentrated, and purified by silica gel chromatography (methanol:dichloromethane), to afford the title compound (0.93 g).


25

Step F Preparation of 2-[4-[3-piperidinopropoxy]phenyl]-1-(methanesulfonyl)indole

30


A mixture of immobilized triphenylphosphine resin (330 mg, 1.0 meq (Fluka)), and the product of Step E (140 mg, 0.50 mmol) in tetrahydrofuran (6.0 mL) was treated with 3-(piperidin-1-yl)propanol (143 mg, 1.0 mmol) followed by

diethylazidodicarboxylate (0.16 mL, 1.1 mmol). The reaction was shaken for 20 hr. and filtered. The filtrate was concentrated in vacuo and the residue purified by silica gel chromatography (methanol/ethyl acetate) to afford pure title compound (97 mg). MS (ESI) m/z 413 (MH^+); 1H -NMR ($CDCl_3$) δ 8.13 (d, 1H), 7.59 (d, 1H), 7.50 (d, 2H), 7.36 (m, 2H), 6.97 (d, 2H), 6.68 (s, 1H), 4.08 (t, 2H), 2.72 (s, 3H), 2.4 (m, 6H), 1.63 (m, 6H), 1.45 (m, 2H).

Example 2


2-[4-[3-Piperidinopropoxy]phenyl]-1H-indole
 $K_i = 48$ nM

A solution of the product from Step F, Example 1 (41.4 mg, 0.10 mmol) in methanol (2.0 mL) was treated with potassium hydroxide (1.0 mL, 40% aq). The reaction was stirred at 40° C for 48 hours and concentrated in vacuo. The residue was purified by silica gel chromatography (methanol:dichloromethane) to provide pure title compound (3.7 mg). MS (ESI) m/z 335 (MH^+); 1H -NMR ($CDCl_3$) δ 8.19 (bs, 1H), 7.48 (d, 2H), 7.27 (m, 2H), 7.07 (t, 1H), 7.00 (t, 1H), 6.86 (d, 2H), 6.61 (s, 1H), 3.96 (t, 2H), 2.5 (m, 6H), 1.4 (m, 8H).

Example 3


2-[4-[2-[1-(methyl)-2-pyrrolidinyl]ethoxy]phenyl]-1-(methylsulfonyl)-1H-indole
 $K_i = 77$ nM

The title compound was obtained (70 mg) by the same general method as Example 1 by substituting 2-ethoxy-1-methylpyrrolidine for 3-(piperdin-1-yl)propanol in step F. MS (ESI) m/z 399 (MH^+); 1H -NMR ($CDCl_3$) δ 8.13 (d, 1H), 7.60 (d, 1H), 7.50 (2, 2H), 7.37 (m, 2H), 6.97 (d, 2H), 6.68 (s, 1H), 4.08 (m, 2H), 3.12 (m, 1H), 2.72 (s, 3H), 2.39 (s, 3H), 2.1-1.7 (m, 8H).

Example 4


2-[4-[2-[1-(methyl)-2-pyrrolidinyl]ethoxy]phenyl]-1H-indole
 $K_i = 100 \text{ nM}$

The title compound was obtained (14.3 mg) by the same general method as Example 2 by substituting the product of Example 3 for the product of example 1 as the starting material. MS (ESI) m/z 321 (MH^+); 1H -NMR ($CDCl_3$) δ 8.15 (bs, 1H), 7.49 (d, 1H), 7.47 (d, 2H), 7.26 (d, 1H), 7.04 (t, 1H), 6.98 (t, 1H), 6.85 (d, 2H), 6.59 (s, 1H), 3.95 (m, 2H), 2.96 (t, 1H), 2.23 (s, 3H), 2.1-1.7 (m, 8H).

Example 5

2-[4-[1-(methyl)-4-piperidinyl]oxyphenyl]-1-(methylsulfonyl)-1H-indole
 $K_i = 107 \text{ nM}$


The title compound was obtained (54.8 mg) by the same general method as Example 1 by substituting 4-hydroxy-1-methylpiperidine for 3-(1-piperidinyl) propanol in Step F. MS (ESI) m/z 385 (MH^+); 1H -NMR ($CDCl_3$) δ 8.13 (d, 1H), 7.59 (d, 1H), 7.50 (d, 2H), 7.37 (m, 2H), 6.96 (d, 2H), 6.68 (s, 1H), 4.41 (m, 1H), 2.76 (m, 2H), 2.73 (s, 3H), 2.34 (s, 3H), 2.07 (m, 2H), 1.92 (m, 2H), 1.78 (m, 2H).

Example 6

2-[4-[1-(methyl)-4-piperidinyl]oxyphenyl] 1H-indole
 $K_i = 390 \text{ nM}$

The title compound was obtained (13.8 mg) by the same general method as Example 2 by substituting the product of Example 5 for the product of example 52 as the starting material. MS (ESI) m/z 307 (MH^+); 1H -NMR ($CDCl_3$) δ 8.36 (bs, 1H), 7.63 (d, 1H), 7.60 (d, 2H), 7.41 (d, 1H), 7.19 (t, 1H), 7.13 (t, 1H), 7.00 (d, 2H), 6.73 (s, 1H), 4.42 (m, 1H), 2.76 (m, 2H), 2.40 (m, 2H), 2.36 (s, 3H), 2.09 (m, 2H), 1.92 (m, 2H).


Example 7



2-[4-[3-Dimethylaminopropoxy]phenyl]-1-(methylsulfonyl)-1H-indole
 $K_i = 120$ nM

The title compound was obtained (95 mg) by the same general method as Example 1 by substituting N, N-dimethyl-3-amino-1-propanol for 3-(piperidin-1-yl) propanol in Step F. MS (ESI) m/z 373 (MH^+); 1H -NMR ($CDCl_3$) δ 8.13 (d, 1H), 7.59 (d, 1H), 7.50 (d, 2H), 7.36 (m, 2H), 6.97 (d, 2H), 6.68 (s, 1H), 4.09 (t, 2H), 2.73 (s, 3H), 2.50 (t, 2H), 2.29 (s, 6H), 2.01 (m, 2H).


Example 8



2-[4-[3-Dimethylaminopropoxy]phenyl] 1H-indole
 $K_i = 500$ nM

The title compound was obtained (13.8 mg) by the same general method as Example 2 by substituting the product of Example 7 for the product of Example 1 as the starting material. MS (ESI) m/z 295 (MH^+); 1H -NMR ($CDCl_3$) δ 8.10 (bs, 1H), 7.62 (d, 1H), 7.60 (d, 2H), 7.40 (d, 1H), 7.19 (t, 1H), 7.13 (t, 1H), 7.00 (d, 2H), 6.72 (s, 1H), 4.09 (t, 2H), 2.50 (t, 2H), 2.29 (s, 6H), 2.01 (m, 2H).


Example 9



5 2-[4-[4-Pyridinyl]methoxyphenyl]-1-(methylsulfonyl)-1H-indole
 $K_i = 5000 \text{ nM}$

The title compound was obtained (185 mg) by the same general method as Example 1 by substituting 4-hydroxymethylpyridine for 3-(piperdin-1-yl) propanol in Step F. MS (ESI) m/z 379 (MH^+); 1H -NMR ($CDCl_3$) δ 8.67 (d, 2H), 8.13 (d, 1H), 7.60 (d, 1H), 7.54 (d, 2H), 7.41 (d, 2H), 7.38 (m, 2H), 7.03 (d, 2H), 6.69 (s, 1H), 4.77 (s, 2H), 2.74 (s, 3H).


Example 10



20 2-[4-[2-Diethylaminoethoxy]phenyl]-1-(methylsulfonyl)-1H-indole
 $K_i = 369 \text{ nM}$

The title compound was obtained (140 mg) by the same general method as Example 1 by substituting 2-(N, N-diethylamino)ethanol for 3-(piperdin-1-yl) propanol in Step F. MS (ESI) m/z 387 (MH^+); 1H -NMR ($CDCl_3$) δ 8.14 (d, 1H), 7.59 (d, 1H), 7.50 (d, 2H), 7.16 (m, 2H), 6.97 (d, 2H), 6.67 (s, 1H), 4.12 (t, 2H), 2.91 (t, 2H), 2.73 (s, 3H), 2.67 (q, 4H), 1.10 (t, 6H).


Example 11



35 2-[4-[2-Diethylaminoethoxy]phenyl]-1H-indole
 $K_i = 523 \text{ nM}$

The title compound from Example 10 (38.6 mg, 0.10 mmol) was treated with tetrabutyl ammonium fluoride (4.0 mL, of a 0.5 M in tetrahydrofuran) and stirred for 14 hours at 60°C. The resulting solution was concentrated in vacuo, dissolved in dichloromethane, and washed with water. The organics were then concentrated, and the crude product purified by silica gel chromatography (methanol/ dichloromethane) to afford pure title compound (5.9 mg). MS (ESI) m/z 309 (MH^+); 1H -NMR ($CDCl_3$) δ 8.21 (bs, 1H), 7.53 (d, 1H), 7.51 (d, 2H), 7.31 (d, 1H), 7.09 (t, 1H), 7.04 (t, 1H), 6.90 (d, 2H), 6.64 (s, 1H), 4.06 (t, 2H), 2.88 (t, 2H), 2.63 (q, 4H), 1.04 (t, 6H).

10


Example 12548/467
514/414

15

2-[4-[3-(2-Oxo-pyrrolidino)propoxy]phenyl]-1-(methylsulfonyl)-1H-indole

The title compound was obtained (180 mg) by the same general method as Example 1 by substituting 1-(3-hydroxypropyl)-2-pyrrolidineone for 3-(piperidin-1-yl) propanol in Step F. MS (ESI) m/z 435 ($M+Na$); 1H -NMR ($CDCl_3$) δ 8.12 (d, 1H), 7.59 (d, 1H), 7.49 (d, 2H), 7.36 (m, 2H), 6.95 (d, 2H), 6.67 (s, 1H), 4.03 (t, 2H), 3.55-3.35 (m, 6H), 2.72 (s, 3H), 2.40 (m, 2H), 2.06 (m, 2H).

25


Example 13

30

2-[4-[2-(2-Pyridinyl)ethoxy]phenyl]-1-(methylsulfonyl)-1H-indole

The title compound was obtained (90 mg) by the same general method as Example 1 by substituting 2-(2-hydroxyethyl)pyridine for 3-(piperidin-1-yl)propanol in Step F. MS (ESI) m/z 393 (MH^+); 1H -NMR ($CDCl_3$) δ 8.59 (d, 1H), 8.12 (d, 1H), 7.67 (d, 1H), 7.59 (d, 1H), 7.48 (d, 2H), 7.35 (m, 2H), 7.20 (m, 2H), 6.97 (d, 2H), 6.66 (s, 1H), 4.43 (t, 2H), 3.32 (t, 2H), 2.72 (s, 3H).

35


Example 14546/277.4
574/339

5

2-[4-[2-(2-Pyridinyl)ethoxy]phenyl]-1H-indole

The title compound was obtained (14.5 mg) by the same general method as Example 11 by substituting the product of Example 13 for the product of Example 10 as the starting material. MS (ESI) m/z 315 (MH^+); 1H -NMR ($CDCl_3$) δ 8.52 (d, 1H), 8.45 (bs, 1H), 7.58 (t, 1H), 7.53 (d, 1H), 7.50 (d, 2H), 7.29 (d, 1H), 7.22 (d, 1H), 7.12 (t, 1H), 7.08 (t, 1H), 7.01 (t, 1H), 6.88 (d, 2H), 6.63 (s, 1H), 4.32 (t, 2H), 3.21 (t, 2H).

15


Example 15546/201
574/323

20

2-[3-[3-Piperidinopropoxy]phenyl]-1-(methylsulfonyl)-1H-indole
 $K_i = 33$ nM

The title compound was obtained (84 mg) by the same general method as Example 1 by substituting 3-hydroxybenzaldehyde for 4-hydroxybenzaldehyde in Step B. MS (ESI) m/z 413 (MH^+); 1H -NMR ($CDCl_3$) δ 8.14 (d, 1H), 7.62 (d, 1H), 7.37 (m, 3H), 7.16 (d, 1H), 7.12 (s, 1H), 6.98 (d, 1H), 6.74 (s, 1H), 4.08 (t, 2H), 2.77 (s, 3H), 2.62 (t, 2H), 2.55 (m, 2H), 2.10 (m, 2H), 1.69 (m, 4H), 1.50 (m, 1H).

30

Example 16

2-(4-(3-(4-Methylpiperazino)propoxy)phenyl)indole

 $K_i = 2000 \text{ nM}$ **Step A** Preparation of 4'-(3-chloropropoxy)acetophenone

A solution of 4'-hydroxyacetophenone (20 mmol, 2.72 g), 3-bromopropionyl chloride (21 mmol, 2.07 mL) and potassium carbonate (4.14g, 30.0 mmol) in acetone (50 mL) was heated at reflux for overnight. The salt was filtered off. The solvent was evaporated. After drying in vacuo, the title compound (4.24 g) was collected.

Step B Preparation of 2-(4-(3-chloropropoxy)phenyl)indole


A mixture 4'-(3-chloropropoxy)acetophenone (10 mmol, 2.12 g) and phenylhydrazine (10 mmol, 1.08 g) was heated at 100 °C for 40 min. Then PPA (~5 g) was added and temperature was raised to 130 °C and kept for 10 min. The mixture was cooled down. Water (50 mL) was added. After 2 h, greenish solid was formed and collected via filtration. The solid then was washed by a small amount of methanol (5 mL). After drying in vacuo, the title compound (1.5 g) was obtained.

Step C 2-(4-(3-(4-Methylpiperazino)propoxy)phenyl)indole

The mixture of 2-(4-(3-chloropropoxy)phenyl)indole (1 mmol, 285 mg) and 4-methylpiperazine (2 mL) was heated at 80 °C for 5 h. After concentration, the residue was purified by column chromatography (MeOH/CH₂Cl₂) afforded the title compound (285 mg): ¹H NMR (CDCl₃, 400MHz) δ 8.26 (s, 1H), 7.53 (m, 3H), 7.32 (bd, 1H, $J = 8.1 \text{ Hz}$), 7.1 (td, 1H, $J = 1.1, 7.0 \text{ Hz}$), 7.05 (td, 1H, $J =$

1.1, 7.0 Hz), 6.90 (m, 2H), 6.64 (m, 1H), 3.99 (t, 2H, $J = 6.3$ Hz), 2.48 (m, 10H, $J = 6.4$ Hz), 2.25 (s, 3H), 1.93 (quintet, 2H, $J = 6.3$ Hz); EIMS m/z 350 ($M + H^+$).

5

Example 17

544/373
544/254.09

1-(Methylsulfonyl)-2-(4-(3-(4-methylpiperazino)propoxy)phenyl)indole
 $K_i = 3000$ nM

10

Step A Preparation of 4-(3-chloropropoxy)benzaldehyde

A solution of 4-hydroxybenzaldehyde (100 mmol, 12.2 g), 3-bromopropionyl chloride (101 mmol, 20 mL) and potassium carbonate (20.7 g, 150 mmol) in acetone (250 mL) was heated at reflux for overnight. The salt was filtered off. The solvent was evaporated. Reduced pressure distillation provided the title compound (15 g).

15

Step B Preparation of 1-ethynyl-4-(3-chloropropoxy)benzene

To LDA (2M in THF, 15 mL) in THF (100 mL) at -78°C , TMSCHN_2 (2M in hexanes, 15 mL) was added dropwisely. Ten minutes later, 4-(3-chloropropoxy)benzaldehyde (0.025 mol, 4.97 g) in THF (60 mL) was added. After 1 h stirring at -78°C , the mixture was warmed up and refluxed for 3h.

20

Water (250 mL) was added and extracted by EtOAc (2 x 200 mL). After being dried over Na_2SO_4 and concentration, the title compound (4.8 g) was obtained.

25

Step C Preparation of 1-ethynyl-4-(3-(4-methylpiperazino)propoxy)benzene

30

The mixture of 1-ethynyl-4-(3-chloropropoxy)benzene (2 mmol, 388 mg) and 4-methylpiperazine (2 mL) was heated at 80 °C for 5h. After concentration, the residue was purified by column chromatography (MeOH/CH₂Cl₂) afforded the title compound (400 mg).

5

Step D Preparation of 2-iodo-N-(methanesulfonyl)aniline

To the mixture of the 2-iodo-4-chloroaniline (5.0 g, 20 mmol) and triethylamine (8.3 mL, 60 mmol) in methylene chloride (200 mL), the solution of methanesulfonyl chloride (3.4 mL, 44 mmol) was added slowly. The solution then was stirred at room temperature for 2 h. After being washed by HCl solution (0.5 N, 2 x 100 mL), NaOH solution (0.5 N, 2 x 100 mL), brine (100 mL), the organic layer was dried over Na₂SO₄ and concentrated providing the title compound (6.6 g).

15

Step E Preparation of 1-(methylsulfonyl)-2-(4-(3-(4-methylpiperazino)propoxy)phenyl)indole

The mixture of 1-ethynyl-4-(3-(4-methylpiperazino)propoxy)benzene (230 mg, 0.89 mmol), 2-iodo-N-(methanesulfonyl)aniline (0.89 mmol, 296 mg), CuI (17 mg, 0.089 mmol), Pd(PPh₃)₂Cl₂ (32 mg, 0.045 mmol) and triethylamine (0.5 mL) in DMF (5 mL) was stirred at 80 °C for overnight. After concentration, water (20 mL) was added and extracted by methylene chloride (3 x 20 mL). The organics was concentrated and purified by column chromatography afforded the title compound (260 mg): ¹H NMR (CDCl₃, 400MHz) δ 8.05 (d, 1H, *J* = 8.8 Hz), 7.55 (d, 1H, *J* = 2.1 Hz), 7.50 (td, 2H, *J* = 8.8, 2.1 Hz), 7.32 (d, 1H, *J* = 2.1 Hz), 7.30 (d, 1H, *J* = 2.1 Hz), 6.96 (td, 2H *J* = 2.1, 8.8 Hz), 6.60 (d, 1H, *J* = 0.5 Hz), 4.08 (t, 2H, *J* = 6.3 Hz), 2.74 (s, H), 2.55 (m, 10H), 2.33 (s, 3H), 2.02 (quintet, 2H, *J* = 6.3 Hz); EIMS *m/z* 462 (M + H⁺).

30

F. Biological Examples

Biological Example 1

1(A) Transfection of cells with human histamine receptor

- 5 A 10 cm tissue culture dish with a confluent monolayer of SK-N-MC cells was split two days prior to transfection. Using sterile technique the media was removed and the cells were detached from the dish by the addition of trypsin. One fifth of the cells were then placed onto a new 10 cm dish. Cells were grown in a 37°C incubator with 5% CO₂ in Minimal Essential Media Eagle with
- 10 10% Fetal Bovine Serum. After two days cells were approximately 80% confluent. These were removed from the dish with trypsin and pelleted in a clinical centrifuge. The pellet was then re-suspended in 400 µL complete media and transferred to an electroporation cuvette with a 0.4cm gap between the electrodes (Bio-Rad #165-2088). One µg supercoiled H₃ receptor cDNA
- 15 was added to the cells and mixed. The voltage for the electroporation was set at 0.25 kV, the capacitance is set at 960 µF.

- After electroporation the cells were diluted into 10 mL complete media and plated onto four 10cm dishes. Due to the variability in the efficiency of electroporation, four different concentrations of cells were plated. The ratios
- 20 used were: 1:20, 1:10, and 1:5, with the remainder of the cells being added to the fourth dish. The cells were allowed to recover for 24 hours before adding the selection media (complete media with 600 µg/ml G418). After 10 days dishes were analyzed for surviving colonies of cells. Dishes with well-isolated colonies were used. Cells from individual colonies were isolated and tested.
- 25 SK-N-MC cells were used because they give efficient coupling for inhibition of adenylate cyclase. The clones that gave the most robust inhibition of adenylate cyclase in response to histamine were used for further study.

1(B) [3H]-N-methylhistamine binding

- 30 Cell pellets from histamine H₃ receptor-expressing SK-N-MC cells were homogenized in 20 mM TrisHCl/0.5mM EDTA. Supernatants from a 800 g spin were collected, re-centrifuged at 30,000 g for 30 minutes. Pellets were rehomogenized in 50 mM Tris/5mM EDTA (pH 7.4). Membranes were

incubated with 0.8 nM [³H]-N-methylhistamine plus/minus test compounds for 45 minutes at 25°C and harvested by rapid filtration over GF/C glass fiber filters (pretreated with 0.3% polyethylenimine) followed by four washes with ice cold buffer. Filters were dried, added to 4 mL scintillation cocktail and then
 5 counted on a liquid scintillation counter. Non-specific binding was defined with 10 µM histamine. PK_i values were calculated based on a K_D of 800 pM and a ligand concentration ([L]) of 800 pM according to the formula:

$$K_i = (IC_{50}) / (1 + ([L] / (K_D)))$$

10

11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
61
62
63
64
65
66
67
68
69
70
71
72
73
74
75
76
77
78
79
80
81
82
83
84
85
86
87
88
89
90
91
92
93
94
95
96
97
98
99
100
101
102
103
104
105
106
107
108
109
110
111
112
113
114
115
116
117
118
119
120
121
122
123
124
125
126
127
128
129
130
131
132
133
134
135
136
137
138
139
140
141
142
143
144
145
146
147
148
149
150
151
152
153
154
155
156
157
158
159
160
161
162
163
164
165
166
167
168
169
170
171
172
173
174
175
176
177
178
179
180
181
182
183
184
185
186
187
188
189
190
191
192
193
194
195
196
197
198
199
200
201
202
203
204
205
206
207
208
209
210
211
212
213
214
215
216
217
218
219
220
221
222
223
224
225
226
227
228
229
230
231
232
233
234
235
236
237
238
239
240
241
242
243
244
245
246
247
248
249
250
251
252
253
254
255
256
257
258
259
260
261
262
263
264
265
266
267
268
269
270
271
272
273
274
275
276
277
278
279
280
281
282
283
284
285
286
287
288
289
290
291
292
293
294
295
296
297
298
299
300
301
302
303
304
305
306
307
308
309
310
311
312
313
314
315
316
317
318
319
320
321
322
323
324
325
326
327
328
329
330
331
332
333
334
335
336
337
338
339
340
341
342
343
344
345
346
347
348
349
350
351
352
353
354
355
356
357
358
359
360
361
362
363
364
365
366
367
368
369
370
371
372
373
374
375
376
377
378
379
380
381
382
383
384
385
386
387
388
389
390
391
392
393
394
395
396
397
398
399
400
401
402
403
404
405
406
407
408
409
410
411
412
413
414
415
416
417
418
419
420
421
422
423
424
425
426
427
428
429
430
431
432
433
434
435
436
437
438
439
440
441
442
443
444
445
446
447
448
449
450
451
452
453
454
455
456
457
458
459
460
461
462
463
464
465
466
467
468
469
470
471
472
473
474
475
476
477
478
479
480
481
482
483
484
485
486
487
488
489
490
491
492
493
494
495
496
497
498
499
500
501
502
503
504
505
506
507
508
509
510
511
512
513
514
515
516
517
518
519
520
521
522
523
524
525
526
527
528
529
530
531
532
533
534
535
536
537
538
539
540
541
542
543
544
545
546
547
548
549
550
551
552
553
554
555
556
557
558
559
560
561
562
563
564
565
566
567
568
569
570
571
572
573
574
575
576
577
578
579
580
581
582
583
584
585
586
587
588
589
590
591
592
593
594
595
596
597
598
599
600
601
602
603
604
605
606
607
608
609
610
611
612
613
614
615
616
617
618
619
620
621
622
623
624
625
626
627
628
629
630
631
632
633
634
635
636
637
638
639
640
641
642
643
644
645
646
647
648
649
650
651
652
653
654
655
656
657
658
659
660
661
662
663
664
665
666
667
668
669
670
671
672
673
674
675
676
677
678
679
680
681
682
683
684
685
686
687
688
689
690
691
692
693
694
695
696
697
698
699
700
701
702
703
704
705
706
707
708
709
710
711
712
713
714
715
716
717
718
719
720
721
722
723
724
725
726
727
728
729
730
731
732
733
734
735
736
737
738
739
740
741
742
743
744
745
746
747
748
749
750
751
752
753
754
755
756
757
758
759
760
761
762
763
764
765
766
767
768
769
770
771
772
773
774
775
776
777
778
779
780
781
782
783
784
785
786
787
788
789
790
791
792
793
794
795
796
797
798
799
800
801
802
803
804
805
806
807
808
809
810
811
812
813
814
815
816
817
818
819
820
821
822
823
824
825
826
827
828
829
830
831
832
833
834
835
836
837
838
839
840
841
842
843
844
845
846
847
848
849
850
851
852
853
854
855
856
857
858
859
860
861
862
863
864
865
866
867
868
869
870
871
872
873
874
875
876
877
878
879
880
881
882
883
884
885
886
887
888
889
890
891
892
893
894
895
896
897
898
899
900
901
902
903
904
905
906
907
908
909
910
911
912
913
914
915
916
917
918
919
920
921
922
923
924
925
926
927
928
929
930
931
932
933
934
935
936
937
938
939
940
941
942
943
944
945
946
947
948
949
950
951
952
953
954
955
956
957
958
959
960
961
962
963
964
965
966
967
968
969
970
971
972
973
974
975
976
977
978
979
980
981
982
983
984
985
986
987
988
989
990
991
992
993
994
995
996
997
998
999
1000

G. Other Embodiments

The features and advantages of the invention are apparent to one of ordinary skill in the art. Based on this disclosure, including the summary, detailed description, background, examples, and claims, one of ordinary skill in the art will be able to make modifications and adaptations to various conditions and usages. These other embodiments are also within the scope of the invention.

10

15

What is claimed is: